PS
AGIO icon

Principal Securities’s Agios Pharmaceuticals AGIO Stock Holding History

Principal Securities’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25
Closed -$822 – 3677
2025
Q1 		$822 Hold
25
– – ﹤0.01% 3257
2024
Q4 		$822 Buy
+25
New +$1.17K ﹤0.01% 3250
2024
Q2 		– Sell
-10
Closed -$292 – 3392
2024
Q1 		$292 Hold
10
– – ﹤0.01% 3205
2023
Q4 		$223 Buy
+10
New +$224 ﹤0.01% 3142

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Principal Securities's AGIO Position: Q2 2025 in Review

Principal Securities sold out of Agios Pharmaceuticals (AGIO) in Q2 2025, closing a stake of 25 shares — an estimated $822 sold.

Principal Securities first reported a position in AGIO in Q4 2023 and held it in 4 quarters. The position peaked at $822 in Q1 2025. 215 funds tracked by Wall St. Rank hold AGIO as of Q2 2025.

  • Principal Securities reported no remaining Agios Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Principal Securities sold 25 Agios Pharmaceuticals shares in Q2 2025, an estimated $822.
  • Principal Securities first reported a position in Agios Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Principal Securities's Agios Pharmaceuticals position peaked at $822 in Q1 2025.
  • 215 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2025.

Based on Principal Securities's 13F filing for Q2 2025, filed 11 Aug 2025.